The US FDA has granted approval for Medtronic’s OmniaSecure defibrillation lead intended for insertion in the right ...

Medtronic (NYSE: MDT) announced that it received FDA approval for its OmniaSecure defibrillation lead for right ventricle ...

Omniasecure, which was authorized for placement in the heart’s right ventricle, is the world’s smallest defibrillation lead, ...

Medtronic said its OmniaSecure device can be used to treat potentially life-threatening conditions including ventricular tachyarrhythmias, a heart rhythm disorder where the heart's lower chambers beat ...

Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure defibrillation lead for ...

[18] Left ventricular pacing can induce diaphragmatic stimulation and may affect lead position. Patient anatomy may limit placement options. Atrial and right and left ventricular leads are tested ...

The biggest names in cardiac care gathered in San Diego for the Heart Rhythm Society (HRS) 2025 Annual Meeting.

the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead ...

the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead ...

indicated for stimulation in the right ventricle. Medtronic is also conducting studies on the placement of the OmniaSecure defibrillation lead in the left bundle branch (LBB) region. This approach ...